A ketogenic diet improves the prognosis in a mouse model of peritoneal dissemination without tumor regression

Abstract

Peritoneal dissemination describes a state where tumor cells spread to the surface of the peritoneum and become engrafted. Peritoneal dissemination reduces the quality of life and prognosis of cancer patients. Currently, there are few effective therapies or preventative treatments for peritoneal dissemination. The aim of this study was to evaluate a ketogenic diet, characterized by high fat, moderate protein and low carbohydrate content, as a novel therapy in a mouse model of peritoneal dissemination. BALB/c mice were intraperitoneally inoculated with colon 26, a murine colon adenocarcinoma cell line, to induce experimental peritoneal dissemination. After tumor inoculation, mice were fed a regular or ketogenic diet. A longer survival time and better health status score, related to improved behavior, was observed in the ketogenic diet group compared with the regular diet group. In addition, the weight of ascites was significantly smaller and the anemia symptoms, number of red blood cell, hemoglobin and hematocrit, were improved in the ketogenic diet group compared with the regular diet group. However, the tumor weight was not significantly smaller in the ketogenic diet group compared with the regular diet group. These data suggest that a ketogenic diet might be a potential preventive therapy for peritoneal dissemination.

Anti-tumor effects of ketogenic diets and their synergism with other treatments in mice: Bayesian evidence synthesis of 1755 individual mouse survival data

“…The primary PubMed search resulted in 184 hits of which 156 were discarded after title, abstract, or full-text screening, resulting in 28 articles for inclusion [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] . An additional 15 articles were retrieved from my personal library [20] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] , [76] .…”

Cancer Treatment With the Ketogenic Diet: A Systematic Review and Meta-analysis of Animal Studies

“…A total of 6 articles ( 6 , 28 , 29 , 31 , 32 , 37 ), including 7 studies, reported the effects of KD supplementation on tumor weight in animal models. The overall effects were estimated using a random-effect model because significant heterogeneity was found ( I 2 = 90%, p = 0.000).…”

“…The efficacy of KD may also be influenced by cancer type or even subtype, genetic background, and tumor-associated syndromes. KD with a ratio of 4:1 did not slow the growth of spontaneous medulloblastoma tumors or allograft flank tumors ( 43 ), while it was reported to be anti-tumor in other cancer models, including glioblastoma ( 7 ) and colon cancer ( 32 ). Meanwhile, one study indicated that the anti-neuroblastoma effects of KD were considerably attenuated in SKN-BE(2) neuroblastoma xenografts, which carried MYCN amplification, TP53 mutation (p.C135F), and chromosome 1p loss of heterozygosity, compared to SH-SY5Y xenografts which are TP53 wild-type and non-MYCN amplified ( 42 ).…”

Role of β-hydroxybutyrate as regulator of cell death pathway in experimental cancer model

“…Mice were randomly divided into five equal groups of 10 mice each as follows: Group N (negative control group) that received intraperitoneal injection of saline at a dose of 20 ml /kg.Group E (EAC-bearing group) which was injected intraperitoneally by Ehrlich's ascites carcinoma (EAC) cells (1X 10 6 ) cells/mouse. The day zero was designated as the day of the first injection (Kasumi and Sato, 2019) [6] . Group E+K (EAC-bearing group co-treated with ketone bodies) and these mice were received a ketogenic diet at the day of tumour inoculation for two weeks (Kasumi and Sato, 2019) [6] .…”